Advanced glycation endproducts--role in pathology of diabetic complications.

[1]  J. Baynes,et al.  Effects of Aspirin on Glycation, Glycoxidation, and Crosslinking of Collagen , 2005 .

[2]  M. Slevin,et al.  Aminosalicylic acid reduces the antiproliferative effect of hyperglycaemia, advanced glycation endproducts and glycated basic fibroblast growth factor in cultured bovine aortic endothelial cells: Comparison with aminoguanidine , 2003, Molecular and Cellular Biochemistry.

[3]  E. Cotlier.  Aspirin effect on cataract formation in patients with rheumatoid arthritis alone or combined to diabetes , 1981, International Ophthalmology.

[4]  M. Slevin,et al.  Effect of glycation on basic fibroblast growth factor induced angiogenesis and activation of associated signal transduction pathways in vascular endothelial cells: Possible relevance to wound healing in diabetes , 2004, Angiogenesis.

[5]  V. D’Agati,et al.  Blockade of receptor for advanced glycation endproducts: a new target for therapeutic intervention in diabetic complications and inflammatory disorders. , 2003, Archives of biochemistry and biophysics.

[6]  Paul J Thornalley.  Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. , 2003, Archives of biochemistry and biophysics.

[7]  M. Peppa,et al.  Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. , 2003, Diabetes.

[8]  H. Founds,et al.  Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. , 2003, Archives of biochemistry and biophysics.

[9]  T. Spector,et al.  Level of an advanced glycated end product is genetically determined: a study of normal twins. , 2003, Diabetes.

[10]  T. Yoshikawa,et al.  Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. , 2003, Diabetes research and clinical practice.

[11]  Alan W. Stitt,et al.  The role of advanced glycation in the pathogenesis of diabetic retinopathy. , 2003, Experimental and molecular pathology.

[12]  E. Fisher,et al.  Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. , 2003, Atherosclerosis.

[13]  D. Graves,et al.  A role for advanced glycation end products in diminished bone healing in type 1 diabetes. , 2003, Diabetes.

[14]  J. Baynes,et al.  AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats. , 2003, Archives of biochemistry and biophysics.

[15]  A. Heidland,et al.  Genotoxicity of advanced glycation end products in mammalian cells. , 2003, Cancer letters.

[16]  Hiroshi Yamamoto,et al.  Serum levels of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes. , 2003, Journal of diabetes and its complications.

[17]  J. Baynes.  The Maillard Hypothesis on Aging: Time to Focus on DNA , 2002, Annals of the New York Academy of Sciences.

[18]  H. Vlassara,et al.  Diabetes and advanced glycation endproducts , 2002, Journal of internal medicine.

[19]  A. Schmidt,et al.  Receptor for advanced glycation endproducts (RAGE) and the complications of diabetes , 2002, Ageing Research Reviews.

[20]  Hiroshi Yamamoto,et al.  Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. , 2002, Biochemical and biophysical research communications.

[21]  T. Kislinger,et al.  Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. , 2001, The American journal of pathology.

[22]  K. W. Lee,et al.  Similarity of the yellow chromophores isolated from human cataracts with those from ascorbic acid-modified calf lens proteins: evidence for ascorbic acid glycation during cataract formation. , 2001, Biochimica et biophysica acta.

[23]  S. Takasawa,et al.  Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. , 2001, The Journal of clinical investigation.

[24]  U. Eriksson,et al.  Combined Treatment with Vitamin E and Vitamin C Decreases Oxidative Stress and Improves Fetal Outcome in Experimental Diabetic Pregnancy , 2001, Pediatric Research.

[25]  N. Turk,et al.  Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[26]  L. Poston,et al.  Increase of the isoprostane 8-isoprostaglandin f2alpha in maternal and fetal blood of rats with streptozotocin-induced diabetes: evidence of lipid peroxidation. , 2000, American journal of obstetrics and gynecology.

[27]  V. D’Agati,et al.  Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. , 2000, Journal of the American Society of Nephrology : JASN.

[28]  K. Kawano,et al.  The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. , 2000, Metabolism: clinical and experimental.

[29]  Hiroshi Yamamoto,et al.  The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[30]  M. Cooper,et al.  The cross-link breaker, N-phenacylthiazolium bromide prevents vascular advanced glycation end-product accumulation , 2000, Diabetologia.

[31]  S.-M. Kim,et al.  Glycation impairs high-density lipoprotein function , 2000, Diabetologia.

[32]  M. Brownlee,et al.  Negative consequences of glycation. , 2000, Metabolism: clinical and experimental.

[33]  R. Bucala,et al.  Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts. , 2000, Bioconjugate chemistry.

[34]  D. Yue,et al.  Functional and structural abnormalities in the nerves of Type I diabetic baboons: aminoguanidine treatment does not improve nerve function , 2000, Diabetologia.

[35]  Paul J Thornalley,et al.  Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. , 1999, The Biochemical journal.

[36]  T. Kislinger,et al.  N ε-(Carboxymethyl)Lysine Adducts of Proteins Are Ligands for Receptor for Advanced Glycation End Products That Activate Cell Signaling Pathways and Modulate Gene Expression* , 1999, The Journal of Biological Chemistry.

[37]  P. Riederer,et al.  High molecular weight hyaluronic acid inhibits advanced glycation endproduct‐induced NF‐κB activation and cytokine expression , 1999 .

[38]  M. Boshtam,et al.  Anti-oxidant effect of flavonoids on hemoglobin glycosylation. , 1999, Pharmaceutica acta Helvetiae.

[39]  Paul J Thornalley,et al.  Teratogenicity of 3-deoxyglucosone and diabetic embryopathy. , 1998, Diabetes.

[40]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[41]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[42]  A. Stevens.  The contribution of glycation to cataract formation in diabetes. , 1998, Journal of the American Optometric Association.

[43]  J. Baynes,et al.  Role of the Maillard Reaction in Aging of Tissue Proteins , 1998, The Journal of Biological Chemistry.

[44]  R. O. Stuart,et al.  Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. , 1998, Kidney international.

[45]  A. Schmidt.  Suppression of accelerated diabetic atherosclerosis by soluble receptor for age (srage) , 1998 .

[46]  R. Bucala,et al.  Tobacco smoke is a source of toxic reactive glycation products. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[47]  R. Bucala,et al.  Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. , 1997, Metabolism: clinical and experimental.

[48]  T. Miyazaki,et al.  Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. , 1997, The Journal of clinical investigation.

[49]  R. Bucala.  Lipid and lipoprotein modification by advanced glycosylation end‐products: role in atherosclerosis , 1997, Experimental physiology.

[50]  E. Kohner,et al.  Toxic action of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy , 1997, Diabetologia.

[51]  C. A. Aguilar Salinas,et al.  Vitamin E modifies neither fructosamine nor HbA1c levels in poorly controlled diabetes. , 1996, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[52]  H. Vlassara.  Advanced glycation end-products and atherosclerosis. , 1996, Annals of medicine.

[53]  N. Nakamura,et al.  Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. , 1996, Biochemical and biophysical research communications.

[54]  G. Jerums,et al.  Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. , 1996, Kidney international.

[55]  J. Bernhagen,et al.  An agent cleaving glucose-derived protein crosslinks in vitro and in vivo , 1996, Nature.

[56]  T. Nakamura,et al.  Acceleration of wound healing in diabetic mice by basic fibroblast growth factor. , 1996, Biological & pharmaceutical bulletin.

[57]  E. Hirasaki,et al.  Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats. , 1996, European journal of endocrinology.

[58]  T. Miyata,et al.  Advanced glycation end-products in diabetic nephropathy. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[59]  R. Bucala,et al.  Advanced glycosylation end products in diabetic renal and vascular disease. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[60]  J. Baynes,et al.  N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. , 1995, Biochemistry.

[61]  A. Gugliucci,et al.  Histones from diabetic rats contain increased levels of advanced glycation end products. , 1995, Biochemical and biophysical research communications.

[62]  M. Smith,et al.  Advanced Maillard reaction end products are associated with Alzheimer disease pathology , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[63]  Paul J Thornalley,et al.  Formation of methylglyoxal-modified proteins in vitro and in vivo and their involvement in AGE-related processes. , 1995, Contributions to nephrology.

[64]  Yong Ming Li,et al.  Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. Grundy,et al.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[66]  M. Brownlee,et al.  Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. , 1994, The Journal of clinical investigation.

[67]  E. Friedman,et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.

[68]  E. Kohner,et al.  The Effect of Aminoguanidine and Tolrestat on Glucose Toxicity in Bovine Retinal Capillary Pericytes , 1994, Diabetes.

[69]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[70]  V. Monnier,et al.  Maillard reactions in chemistry, food, and health , 1994 .

[71]  S. Wolff,et al.  Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. , 1993, Biochemical pharmacology.

[72]  T. Lyons,et al.  Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. , 1993, The Journal of clinical investigation.

[73]  J. V. Hunt,et al.  Oxidative alterations in the experimental glycation model of diabetes mellitus are due to protein-glucose adduct oxidation. Some fundamental differences in proposed mechanisms of glucose oxidation and oxidant production. , 1993, The Biochemical journal.

[74]  T. Lyons,et al.  Accumulation of Maillard reaction products in skin collagen in diabetes and aging. , 1993, The Journal of clinical investigation.

[75]  E. Friedman,et al.  Hemoglobin-AGE: a circulating marker of advanced glycosylation. , 1992, Science.

[76]  V. Monnier,et al.  Maillard Reaction-Mediated Molecular Damage to Extracellular Matrix and Other Tissue Proteins in Diabetes, Aging, and Uremia , 1992, Diabetes.

[77]  R Blakytny,et al.  Prevention of cataract in diabetic rats by aspirin, paracetamol (acetaminophen) and ibuprofen. , 1992, Experimental eye research.

[78]  M. Brownlee,et al.  Mechanistic Studies of Advanced Glycosylation End Product Inhibition by Aminoguanidine , 1992, Diabetes.

[79]  H. Hammes,et al.  Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[80]  H. Hammes,et al.  Erratum: Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy (Proc. Natl. Acad. Sci. USA (December 15, 1991) 88:24 (11555-11558)) , 1992 .

[81]  E. Ellis,et al.  Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. , 1991, Metabolism: clinical and experimental.

[82]  Z. Makita,et al.  Human and rat mesangial cell receptors for glucose-modified proteins: potential role in kidney tissue remodelling and diabetic nephropathy , 1991, The Journal of experimental medicine.

[83]  J. Baynes.  Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[84]  J. Oram,et al.  Nonenzymatic Glycosylation of HDL and Impaired HDL-Receptor–Mediated Cholesterol Efflux , 1991, Diabetes.

[85]  D. Giugliano,et al.  Vitamin E Reduction of Protein Glycosylation in Diabetes: New Prospect for Prevention of Diabetic Complications? , 1991, Diabetes Care.

[86]  S. Domschke,et al.  Vitamin E Reduction of Protein Glycosylation in Diabetes , 1991 .

[87]  J. Harding,et al.  The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteins. , 1990, Experimental eye research.

[88]  T. Brown,et al.  Identification of fructose 3-phosphate in the lens of diabetic rats. , 1990, Science.

[89]  A. Cerami,et al.  Novel pyrroles from sulfite-inhibited Maillard reactions: insight into the mechanism of inhibition , 1988 .

[90]  T. Lyons,et al.  Glycosylation of Low-Density Lipoprotein Enhances Cholesteryl Ester Synthesis in Human Monocyte-Derived Macrophages , 1988, Diabetes.

[91]  A. Cerami,et al.  Specific Macrophage Receptor Activity for Advanced Glycosylation End Products Inversely Correlates With Insulin Levels In Vivo , 1988, Diabetes.

[92]  F. Bieber,et al.  Lack of relation of increased malformation rates in infants of diabetic mothers to glycemic control during organogenesis. , 1988, The New England journal of medicine.

[93]  S P Wolff,et al.  Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. , 1987, The Biochemical journal.

[94]  R. E. Perry,et al.  Progressive changes in lens crystallin glycation and high-molecular-weight aggregate formation leading to cataract development in streptozotocin-diabetic rats. , 1987, Experimental eye research.

[95]  A. Cerami,et al.  Trapped Immunoglobulins on Peripheral Nerve Myelin From Patients With Diabetes Mellitus , 1986, Diabetes.

[96]  A. Cerami,et al.  Nonenzymatic Glycosylation Products on Collagen Covalently Trap Low-Density Lipoprotein , 1985, Diabetes.

[97]  A. Cerami,et al.  Recognition and Uptake of Human Diabetic Peripheral Nerve Myelin by Macrophages , 1985, Diabetes.

[98]  P. Higgins,et al.  Reaction of monosaccharides with proteins: possible evolutionary significance. , 1981, Science.

[99]  Samir K. Srivastava,et al.  Role of glycosylation in protein disulfide formation and cataractogenesis. , 1980, Experimental eye research.